News

Our Healthcare News

Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy

Zurich-Schlieren, SWITZERLAND—Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that…  

Oct 03 2019

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen

Approvals in the United States and…  

Sep 09 2019

Molecular Partners' Strategic Partner Allergan Announced Today that EMA has Validated the Marketing Authorisation Application for Abicipar

ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that…  

Aug 06 2019

Molecular Partners and Amgen Announce Strategic Collaboration in Immuno-Oncology

ZURICH-SCHLIEREN, Switzerland and THOUSAND OAKS, California –– Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics, and Amgen (NASDAQ:AMGN)…  

Dec 19 2018

Revance's RT002 Demonstrates Unprecedented Efficacy and Duration in Largest-Ever Aesthetic Neuromodulator Clinical Program

NEWARK, California—(BUSINESS WIRE)—Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced its long-acting neuromodulator…  

Dec 04 2018

Revance Announces China Market License Agreement with Fosun Pharma for RT002

NEWARK, Califronia.—(BUSINESS WIRE)—Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company…  

Dec 04 2018

Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to Be the First Fixed 12-Week Anti-VEGF Therapeutic

Zurich-Schlieren, SWITZERLAND—Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the phase…  

Oct 29 2018

Molecular Partners and AstraZeneca Announce Collaboration on Molecular Partners' Ongoing Oncology Clinical Study with MP0250 in EGFR-Mutated NSCLC

ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that Molecular Partners…  

Apr 11 2018

Thermo Fisher Scientific Acquires IntegenX, Leading Provider of Rapid DNA Technology for Human Identification

CARLSBAD, California—Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has acquired IntegenX Inc., which provides a rapid DNA platform…  

Mar 16 2018